PCSK9 Gene Editing: One Shot to Fight Heart Disease
VRRV-102 is a single gene-editing infusion that permanently switches off the PCSK9 gene, cutting LDL cholesterol 62% and sustaining results for 18 months in Phase 1 trials. Dr. Wissner-Gross calls it 'squinting at it — a one-time shot to cure heart disease.'
